Environmental Engineering Reference
In-Depth Information
drugs and novel means of delivery particularly using nanocarriers can allow
branded drugs to be rescued from abyss of generic competition (may be called
resurrection of drugs). Priority should be given to drug delivery research due to its
low investment and quick return. It is the best way to give technology leadership in
pharmaceutical industry due to problems in new chemical entity (NCE) research
and stricter patent laws. Because of biodegradability and nontoxicity of the
bio-polysaccharides, they should be explored for their potential in designing
nanomicellar carriers for targeted drug delivery. There is a lot of opportunity in
this field for enhancing drug effects with the use of a minimum amount of drugs and
thereby reducing the dose related toxicity of the drugs. Some drugs which possesses
significant bioactivity as obvious from high throughput screening but are not
considered for future development could find a new direction for their development.
References
1. Thompson D, Chaubal MV (2000) Cyclodextrins (CDS)-excipients by definition, drug deliv-
ery systems by function (Part I: Injectable applications). Drug Deliv Technol 2:34-38
2. Shabner BA, Collings JM (1990) Cancer chemotherapy. In: Principles and practice. Humana
Press, Philadelphia, PA
3. Okada J, Cohen S et al (1995) In vitro evaluation of polymerized liposomes as an oral drug
delivery system. Pharm Res 12:576-582
4. Toorisaka E, Ono H et al (2003) Hypoglycemic effect of surfactant-coated insulin solubilized
in a novel solid-in-oil-in-water (S/O/W) emulsion. Int J Pharm 252:271-274
5. Uchida M, Kato Y et al (2000) Involvement of nitric oxide from nerves on diarrhea induced by
castor oil in rats. Jpn J Pharmacol 82:168-170
6. Ray R, Kibbe AH et al (2003) Handbook of pharmaceutical excipients. APhA Publications,
Washington, DC
7. Rosen MJ (2004) Surfactants and interfacial phenomena. Wiley Interscience, New York, NY
8. Kim S-C, Chang E-O et al. (2001) Biodegradable polymeric micelle-type drug composition
and method for the preparation thereof. US Patent 6322805B1
9. Yokogawa K, Nakashima E et al (1990) Relationships in the structure-tissue distribution of
basic drugs in the rabbit. Pharm Res 7:691-696
10. Lipinski CA (2000) Drug-like properties and the causes of poor solubility and poor perme-
ability. J Pharmacol Toxicol Methods 44:235-249
11. Horter D, Dressman JB (2001) Influence of physicochemical properties on dissolution of drugs
in the gastrointestinal tract. Adv Drug Deliv 46:75-87
12. Fernandez AM, Van Derpoorten K et al (2001)
N
-Succinyl-(beta-alanyl-Lleucyl-L-alanyl-L-
leucyl) doxorubicin: an extracellularly tumor-activated prodrug devoid of intravenous acute
toxicity. J Med Chem 44:3750-3753
13. Torchilin VP, Trubetskoy VS (1995) Which polymers can make nanoparticulate drug carriers
long-circulating? Adv Drug Deliv Rev 16:141-155
14. Maeda H, Wu J et al (2000) Tumor vascular permeability and the EPR effect in macromolec-
ular therapeutics: a review. J Cont Rel 65:271-284
15. Torchilin VP (1998) Polymer-coated long-circulating microparticular pharmaceuticals. J
Microencapsul 15:1-19
16. Gref R, Minamitake J et al (1994) Biodegradable long-circulating polymeric nanospheres.
Science 263:1600-1603
